A5234

International Trial of Modified Directly Observed Therapy versus Self-Administered Therapy for Participants with First Virologic Failure on a Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Antiretroviral Regimen

Sponsor: US National Institute of Allergy and Infectious Diseases (NIAID)

Protocol Summary: A5234 was a randomized, prospective, open label, controlled study of participants experiencing virologic failure on their first non-nucleoside reverse transcriptase (NNRTI)-based highly active antiretroviral therapy (HAART) regimen. At entry, all participants stopped the NNRTI-containing regimen, switched to one of the study regimens, and were randomized to directly observed therapy (DOT) or self-administered standard of care. Adherence was measured using Medication Event Monitoring System (MEMS) caps, self reports, and medication diaries completed by the DOT partner

Years: 2010 – 2012

Investigator: Anthony Chisada

Location: Parirenyatwa CRS

ACTG

Completed Study

Publication:

Comments are closed.

Website by Canton Becker